Nanjing Leads Biolabs Co., Ltd. has secured priority review in China for the biologics licence application covering opamtistomig as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma after at least two previous systemic treatment lines. The July 10, 2026 decision moves the Hong Kong-listed biotechnology company, traded under stock code 9887, closer to a possible first commercial approval for its lead PD-L1 and 4-1BB bispecific antibody.
China’s Center for Drug Evaluation accepted the application into the National Medical Products Administration’s priority review and approval procedure. The designated review period is 130 working days, compared with 200 working days under the ordinary route, although the shorter target does not guarantee approval or prevent regulators from requesting additional information. Leads Biolabs said it has started preparing for a potential commercial launch while continuing to work with the regulator.
The application also tests a more ambitious proposition. Leads Biolabs is not merely seeking a niche approval for a rare cancer. It is attempting to establish opamtistomig as proof that conditional 4-1BB activation can strengthen checkpoint inhibition in tumours that have historically responded poorly to conventional immunotherapy.
Why does China’s priority review decision materially change the opamtistomig timeline?
Priority review gives Leads Biolabs greater visibility around the regulatory process and potentially brings opamtistomig to patients several months earlier than an ordinary assessment would allow. For a clinical-stage company approaching its first product launch, the difference can affect manufacturing plans, medical-affairs recruitment, hospital engagement and the timing of commercial expenditure.
The designation should not be confused with an approval. Regulators must still examine the pivotal trial’s efficacy, safety, manufacturing controls, product consistency and benefit-risk profile. A review can be delayed if the submitted data are incomplete or if questions emerge concerning trial interpretation or production readiness.
Nevertheless, acceptance into the accelerated procedure indicates that Chinese regulators regard the indication as involving a serious unmet medical need. Leads Biolabs said the priority timeline is 130 working days, reducing the target from the 200 working days used for a standard biologics licence application.
This creates a more defined commercial planning window. The company can begin preparing market-access materials, treatment-centre education and supply arrangements, but spending too aggressively before approval would create its own financial risk. The sensible approach is to build launch capability in stages while preserving flexibility in case the regulator asks for further evidence.
Why are patients with previously treated EP-NEC left with so few effective options?
Extrapulmonary neuroendocrine carcinoma is a rare and aggressive cancer that develops outside the lungs. It can originate in the gastrointestinal tract, pancreas, bladder, reproductive organs or other locations, creating a medically diverse patient population that is difficult to study through large conventional trials.
Advanced disease is commonly treated initially with platinum-based chemotherapy, often using a strategy adapted from small-cell lung cancer because the two diseases can share aggressive biological characteristics. Responses may occur, but they are frequently temporary and the cancer can progress rapidly.
Leads Biolabs said median overall survival with first-line platinum chemotherapy is approximately one year. After progression, particularly among patients who have already received two or more systemic regimens, available treatments have produced reported response rates of zero to 10 percent and median survival of only three to four months. The company also said no regulatory authority has approved a therapy specifically for EP-NEC.
The absence of a globally recognised later-line standard is central to the regulatory strategy. When patients have exhausted available chemotherapy and there is no established active comparator, a single-arm trial showing substantial and durable tumour responses may become more persuasive than it would be in a crowded indication with several proven treatments.
The rarity of the disease creates another problem. EP-NEC can be difficult to diagnose consistently, and patients may be dispersed across many hospitals. That fragmentation slows trial enrolment and can delay referral to specialist centres with experience managing neuroendocrine malignancies.
What clinical evidence supports the opamtistomig biologics licence application?
The Chinese application is supported by a pivotal single-arm registrational study evaluating opamtistomig in patients with advanced EP-NEC whose disease progressed after at least two prior systemic treatment lines. The multicentre study was led by Professor Shen Lin of Peking University Cancer Hospital, and enrolment was completed in August 2025.
Leads Biolabs has described the pivotal results as positive, but it has not yet publicly disclosed the complete dataset underlying the submission. The precise objective response rate, duration of response, progression-free survival, overall survival and severe adverse-event profile from the registrational population will be essential for assessing how strong the approval case really is.
Earlier clinical data provide some context. In the Phase 1 and Phase 2 monotherapy programme, patients receiving the recommended Phase 2 dose of 15 milligrams per kilogram achieved an overall response rate of 33.3 percent and a disease-control rate of 48.5 percent. Among patients treated in the third line or later, 27.8 percent experienced a partial response.
Those results appear encouraging against the weak historical response rates reported with existing later-line approaches. They still came from relatively small patient groups, and comparisons with historical outcomes can be affected by differences in eligibility, disease location, previous treatment and clinical assessment.
The pivotal study must therefore show that the earlier signal remained consistent in a larger, more clearly defined registrational population. Response durability will matter as much as the percentage of patients whose tumours shrink. A short-lived response may provide less clinical value in a fast-moving cancer than a smaller number of sustained responses.
How does opamtistomig combine checkpoint blockade with conditional 4-1BB activation?
Opamtistomig, previously known as LBL-024, is designed to bind both PD-L1 and 4-1BB. The PD-L1 component blocks an immune-suppressive pathway used by tumours to weaken T-cell activity, while the 4-1BB component aims to provide a stimulatory signal that expands and reactivates immune cells.
The molecule was developed through Leads Biolabs’ X-Body platform using a two-by-two structure containing two binding domains for each target. Its affinities are intended to favour 4-1BB activation when the antibody is attached to PD-L1-expressing cells, concentrating immune stimulation closer to the tumour rather than activating T cells indiscriminately throughout the body.
That conditional design addresses a known challenge in the 4-1BB field. Earlier systemic 4-1BB agonists showed biological activity but encountered liver toxicity and narrow therapeutic windows. The objective is to preserve the pathway’s ability to reactivate exhausted T cells while reducing uncontrolled activation in healthy tissue.
This mechanism could be relevant in EP-NEC because the disease is frequently described as immunologically cold. Such tumours may contain limited T-cell infiltration and may not respond strongly when treatment blocks PD-1 or PD-L1 without providing an additional stimulatory signal.
Opamtistomig is intended to perform both tasks with one molecule. Whether that design produces a meaningful advantage over a checkpoint inhibitor alone will require comparative evidence. The current registrational study does not appear to include a randomised control arm, so approval may establish activity without fully separating the contribution of each mechanism.
Does the earlier safety profile support repeated 4-1BB pathway activation?
Safety is particularly important because the history of 4-1BB agonism includes programmes limited by liver toxicity and systemic immune activation. Leads Biolabs has said opamtistomig has shown a safety profile broadly comparable with PD-1 or PD-L1 inhibitors, but the detailed pivotal data remain unavailable.
In earlier monotherapy testing at the recommended dose, treatment-related adverse events occurred in 70.3 percent of patients. Grade 3 or higher treatment-related events were reported in 16.2 percent, while treatment-related serious adverse events occurred in 15.3 percent. Treatment-related toxicity led to permanent discontinuation in 2.7 percent of patients.
Common adverse events included anaemia, increased liver enzymes and reduced white-blood-cell counts. These findings do not automatically indicate an unacceptable profile, particularly in heavily pretreated patients with aggressive cancer, but they show why regulators will scrutinise liver function, haematological toxicity and immune-related complications.
The pivotal population may also provide a clearer view of safety at the intended commercial dose. Rare but serious events can be difficult to detect in small dose-escalation cohorts. Longer follow-up will be needed to understand whether repeated dosing creates cumulative liver or immune toxicity.
A manageable monotherapy profile could become commercially important beyond EP-NEC. Leads Biolabs is also combining opamtistomig with chemotherapy in several studies, where overlapping adverse effects may be more challenging than with the antibody alone.
Why is a single-arm pivotal study acceptable but still scientifically vulnerable?
Single-arm trials can support accelerated or conditional approvals in rare, life-threatening cancers when there is no satisfactory treatment and randomising patients to an ineffective control would be difficult. The regulatory argument becomes stronger when the experimental therapy produces responses that are substantially greater and more durable than anything expected from available care.
The design also allows development to move faster in a small patient population. Recruiting enough patients for a large randomised study across a rare and geographically dispersed cancer could take years, delaying access for people with few alternatives.
The limitation is that single-arm studies cannot eliminate selection bias or prove that the treatment improves survival compared with another therapy. Patients who enter a specialist trial may have better health, more favourable tumour biology or stronger supportive care than those represented in historical datasets.
Independent radiological review, clearly defined eligibility criteria and durable responses can reduce some uncertainty. Regulators may still require confirmatory evidence after approval, particularly if the initial decision relies primarily on tumour response rather than mature survival data.
Leads Biolabs has already received permission to initiate a separate pivotal Phase 3 trial of opamtistomig with chemotherapy in first-line advanced EP-NEC. That programme could eventually provide comparative evidence earlier in the disease and strengthen confidence in the molecule’s broader clinical value.
Could a rare-cancer approval support a commercially meaningful launch?
EP-NEC is unlikely to generate the patient volumes associated with lung, breast or gastrointestinal cancers. The first approval could still be strategically valuable because it would transform Leads Biolabs from a research-stage biotechnology company into a commercial organisation with a validated product and manufacturing process.
Launching in a rare cancer presents both opportunities and difficulties. A small number of specialist hospitals may treat a meaningful share of diagnosed patients, allowing focused medical education and commercial deployment. However, inconsistent diagnosis and referral pathways can leave eligible patients unidentified.
The company will need to educate oncologists and pathologists about the distinction between poorly differentiated neuroendocrine carcinoma and better-differentiated neuroendocrine tumours, which can have different biology and treatment requirements. Central pathology review or stronger diagnostic networks may be necessary to ensure that the therapy reaches the intended population.
Pricing and reimbursement will influence adoption. A novel bispecific antibody may carry a substantial treatment cost, while Chinese reimbursement negotiations can require meaningful price concessions in exchange for wider access. Leads Biolabs must balance revenue generation with the need to build clinical use in a rare indication.
Manufacturing readiness is another determinant. Bispecific antibodies involve complex production and quality-control requirements. A first launch will test whether the company can supply consistent commercial batches while maintaining capacity for expanding clinical programmes.
Could EP-NEC approval validate opamtistomig across much larger cancer markets?
Leads Biolabs is evaluating opamtistomig across 13 solid-tumour indications, including non-small-cell lung cancer, small-cell lung cancer, biliary tract cancer, ovarian cancer, gastric cancer, melanoma, hepatocellular carcinoma, oesophageal squamous-cell carcinoma and triple-negative breast cancer. The company has described the programme as a potential pan-cancer immunotherapy backbone.
A first approval would provide regulatory and manufacturing validation, but it would not prove efficacy across all these tumours. The immune environment, PD-L1 expression, treatment history and sensitivity to 4-1BB activation differ considerably between cancer types.
The larger commercial opportunity may lie in combination treatment. Earlier first-line EP-NEC data involving opamtistomig with platinum and etoposide showed a 75 percent objective response rate and a 92.3 percent disease-control rate among 52 evaluable patients. The 15-milligram-per-kilogram group produced an 83.3 percent response rate, although longer follow-up and randomised comparisons are required.
Leads Biolabs is also advancing the antibody in lung and biliary tract cancers. Success in one of those larger indications could alter the asset’s commercial value far more dramatically than an EP-NEC launch alone.
The rare-cancer application should therefore be viewed as an entry point. It gives the company a chance to establish the drug where unmet need is extreme while collecting evidence that may support broader development.
What international pathway remains after a potential Chinese approval?
Opamtistomig received orphan-drug designation from the United States Food and Drug Administration for neuroendocrine carcinoma in November 2024 and fast-track designation for EP-NEC in January 2026. The European Commission also granted orphan designation in January 2026.
These designations can provide regulatory engagement and development incentives, but neither represents approval. Authorities outside China may request additional data, including trials involving international patients or evidence that the Chinese study population is applicable to clinical practice in other regions.
A Chinese approval could nevertheless strengthen global discussions. It would provide a reviewed manufacturing package, a growing post-market safety database and practical experience using the drug in routine care.
Leads Biolabs has not announced a global licensing partner for opamtistomig. The priority review may increase external interest because multinational pharmaceutical companies are actively seeking differentiated Chinese oncology assets with early clinical validation.
The company could retain international rights, enter a regional licensing agreement or structure a broader co-development partnership. Waiting until after approval or more mature data could improve bargaining power, but self-funding an extensive global programme would require substantially greater capital and operational infrastructure.
How did Leads Biolabs shares react to the priority review milestone?
Leads Biolabs shares rose 3.1 percent on July 10 to close at approximately HK$49.92, compared with the previous close of HK$48.42. The stock traded between HK$47.50 and HK$51 during the session, showing a positive but restrained response to the regulatory news.
The shares remained down approximately 6.4 percent over five trading days and 9.5 percent over one month. They were also trading much closer to the lower end of their 52-week range of HK$44.72 to HK$97.50 than to the peak.
That market reaction suggests investors recognised the faster review path without treating it as equivalent to approval. The absence of complete pivotal efficacy and safety data may be limiting enthusiasm, while the company still faces launch spending, reimbursement negotiations and execution risk.
Leads Biolabs listed in Hong Kong in July 2025 after raising approximately $189 million. Its transition toward commercialisation could change how the market values the company, but investors are likely to demand clearer evidence on approval probability, launch timing and revenue potential before assigning a substantial premium.
Which milestones will determine whether priority review becomes a successful launch?
The immediate milestone is completion of the National Medical Products Administration review. Questions from regulators about efficacy, safety or manufacturing could shape both the timeline and the eventual prescribing information.
Publication or conference presentation of the pivotal dataset will be equally important. Investors and oncologists need to see the response rate, duration of response, survival outcomes and adverse-event profile rather than relying only on the company’s description of positive results.
Approval would shift attention toward pricing, reimbursement and hospital uptake. Leads Biolabs must identify eligible patients, support specialist treatment centres and maintain reliable commercial supply without allowing launch expenses to overwhelm its balance sheet.
The first-line Phase 3 programme may become the more consequential long-term test. Later-line approval would address an urgent treatment gap, while a positive randomised study in newly diagnosed advanced EP-NEC could move opamtistomig into a larger patient population and provide stronger evidence of survival benefit.
Priority review has moved Leads Biolabs closer to a milestone few development-stage companies reach: a first product decision. The remaining questions concern the strength of the pivotal data and whether conditional 4-1BB activation can deliver durable antitumour activity without recreating the safety problems that constrained earlier drugs targeting the pathway.
A favourable Chinese decision would give patients with previously treated EP-NEC a dedicated therapeutic option for the first time. It would also give Leads Biolabs something more valuable than a faster regulatory calendar: clinical validation for a mechanism the company hopes can compete across a much broader range of difficult solid tumours.
